Karin Muraszko, M.D., grew up in New Jersey and received her undergraduate degree from Yale University. She then continued to Columbia University in New York where she received her medical degree and completed her residency training in Neurological Surgery and completed fellowships in pediatric neurosurgery.
Following her training at Columbia, Dr. Muraszko was a researcher at the National Institutes for Health for two years before joining the team at the University of Michigan. In 2005, Dr. Muraszko was chosen to head the Department of Neurosurgery at the University of Michigan, becoming the first woman to chair an academic neurosurgery department in the United States.
Dr. Muraszko specializes in pediatric neurosurgery. She is board certified by the American Board of Neurological Surgeons, and is a member of the American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS) along with several pediatric professional associations. Her research interests include Immunotoxin therapy for brain tumors, the biology of brain tumors, Chiari malformations, craniofacial anomalies, congenital anomalies of the brain and spine and hydrocephalus.
Dr. Muraszko lives in Ann Arbor with her husband and two children.
Areas of Interest
Immunotoxin therapy for brain tumors, biology of brain tumors, Chiari malformations, craniofacial anomalies, congenital anomalies of the brain and spine, hydrocephalus.
Pediatric brain and central nervous system tumors, pediatric brain tumors, CNS tumors, spina bifida, hydrocephalus, myelomeningocele, craniofacial anomalies, chiari malformations, spasticity and cerebral palsy, tethered cord syndrome, vascular anomalies, pediatric brain and spine injury, refractory epilepsy, congenital brain and spinal cord anomalies.
Columbia University, College of Physicians & Surgeons, 1981
Neurosurgery, New York Presbyterian Medical Center (Weill Cornell Medical Center), 1988
F.A.C.S., Fellow, American College of Surgeons
- 2013-2015 A non-randomized, open-label dose-finding trial of combined cytotoxic and immune stimulatory strategy for the treatment of resectable primary malignant glioma; Sponsor: Phase ONE
- 2012-2016 The Park-Reeves Syringomyelia Research Consortium; Sponsor: Washington University
- 2011-2013 The Notch signaling pathway in glioblastoma; Sponsor: NIH